| 纯度 | > 98 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AIMP1 |
| Uniprot No | Q12904 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 147-312aa |
| 氨基酸序列 | SKPIDVSRLD LRIGCIITAR KHPDADSLYV EEVDVGEIAP RTVVSGLVNH VPLEQMQNRM VILLCNLKPA KMRGVLSQAM VMCASSPEKI EILAPPNGSV PGDRITFDAF PGEPDKELNP KKKIWEQIQP DLHTNDECVA TYKGVPFEVK GKGVCRAQTM SNSGIK |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AIMP1重组蛋白的3篇文献示例(文献信息为模拟示例，实际文献需通过学术数据库核实)：
1. **文献名称**：*AIMP1 promotes TGF-β-mediated pulmonary fibrosis via extracellular vesicle secretion*
**作者**：Kim, S. H., Park, J. H., et al.
**摘要**：研究通过重组AIMP1蛋白发现其通过激活TGF-β信号通路促进肺成纤维细胞增殖和胶原沉积，揭示其在肺纤维化中的关键作用。
2. **文献名称**：*AIMP1 functions as a cytokine-like molecule in macrophage activation*
**作者**：Lee, Y. S., Kim, K. R., et al.
**摘要**：重组AIMP1蛋白被证实可结合巨噬细胞表面受体(如TLR4)，诱导促炎因子(如TNF-α、IL-6)释放，表明其作为新型免疫调节因子的功能。
3. **文献名称**：*Secreted AIMP1 contributes to tumor microenvironment remodeling*
**作者**：Jeong, E. J., Choi, Y. K., et al.
**摘要**：利用重组AIMP1蛋白验证其在肿瘤微环境中的作用，发现其通过抑制内皮细胞迁移和血管生成，间接抑制肿瘤生长。
4. **文献名称**：*AIMP1 recombinant protein exacerbates neuroinflammation in ALS models*
**作者**：Han, J. M., Kim, J. Y., et al.
**摘要**：研究显示，重组AIMP1蛋白在小胶质细胞中激活NF-κB通路，加剧神经炎症反应，提示其在神经退行性疾病中的潜在病理机制。
**注意**：以上内容为基于AIMP1已知功能的模拟摘要，实际文献需通过PubMed、Google Scholar等平台以关键词“AIMP1 recombinant”“AIMP1 extracellular role”检索。
**Background of AIMP1 Recombinant Protein**
AIMP1 (aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1), also known as EMAP II (endothelial monocyte-activating polypeptide II) or SCYE1. is a cytokine-like protein derived from the multi-tRNA synthetase complex (MSC) in eukaryotes. Initially identified as a non-catalytic component of the MSC, AIMP1 plays critical roles in regulating inflammation, angiogenesis, and immune responses. Under cellular stress or apoptosis, AIMP1 is released from the MSC and functions as a secreted cytokine, binding to receptors such as CXCR3 and CCR5 to activate downstream signaling pathways.
Recombinant AIMP1 protein is produced using biotechnological methods, typically through expression in *E. coli* or mammalian cell systems, followed by purification to ensure high purity and bioactivity. Its recombinant form retains the native protein's functional properties, enabling researchers to study its pleiotropic effects in vitro and in vivo.
AIMP1 is implicated in diverse physiological and pathological processes. It promotes pro-inflammatory responses by stimulating macrophages, endothelial cells, and monocytes, and it regulates extracellular matrix remodeling. Studies highlight its dual role in cancer: while it exhibits anti-tumor activity by inhibiting angiogenesis, chronic overexpression may contribute to tumor progression via immune modulation. Additionally, AIMP1 is linked to neurodegenerative diseases, autoimmune disorders, and viral infections, making it a potential therapeutic target or biomarker.
Research on recombinant AIMP1 has advanced understanding of its structure-function relationships, receptor interactions, and therapeutic applications. Its versatility in modulating immune and inflammatory pathways underscores its significance in both basic research and drug development.
×
